Reactive Astrogliosis predicts Amyloid Accumulation before the Preclinical Stage of Alzheimer's Disease
Unlike fluid neuroinflammation markers, <sup>18</sup>F-SMBT-1 facilitates quantitative assessment of regional differences in reactive astrogliosis across the AD continuum, as well as longitudinal change. Elevated <sup>18</sup>F-SMBT-1 in CU A- predicted Ab accumulation, highlighting the potential of <sup>18</sup>F-SMBT-1 as a prognostic marker in early-stage AD while suggesting modulation of astrocytic function may be a target for AD prevention and treatment.
Authors
- Vincent Doré (ORCID: https://orcid.org/0000-0002-8051-0558)
- Svetlana Bozinovski
- K. Huang
- Miloš D. Ikonomović (ORCID: https://orcid.org/0000-0002-8745-3293)
- Ryuichi Harada (ORCID: https://orcid.org/0000-0001-8538-8814)
- Azadeh Feizpour
- Ishara Paranawithana (ORCID: https://orcid.org/0000-0001-6509-9687)
- Shozo Furumoto (ORCID: https://orcid.org/0000-0002-9296-3079)
- C. C. Rowe
- Brian J. Lopresti
- Rachel S. Mulligan
- Ying Xia
- Pierrick Bourgeat
- Jurgen Fripp
- Nobuyuki Okamura
- Simon M. Laws
- Victor L. Villemagne
Institutions
- Edith Cowan University (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- The University of Melbourne (AU)
- University of Pittsburgh (US)
- Tohoku University (JP)
- Florey Institute of Neuroscience and Mental Health (AU)
- VA Pittsburgh Healthcare System (US)
- Tohoku Medical and Pharmaceutical University Hospital (JP)
- CSIRO Health and Biosecurity (AU)
- Institute of Aging (CA)
- Austin Health (AU)
- Tohoku Medical and Pharmaceutical University (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_109761
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00